Compare FOXF & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | PRTA |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.0M | 539.9M |
| IPO Year | 2013 | 2013 |
| Metric | FOXF | PRTA |
|---|---|---|
| Price | $16.71 | $10.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $30.25 | $19.00 |
| AVG Volume (30 Days) | ★ 614.3K | 453.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,467,321,000.00 | $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | $0.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $13.08 | $4.32 |
| 52 Week High | $31.18 | $11.69 |
| Indicator | FOXF | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 67.15 |
| Support Level | $15.42 | $9.69 |
| Resistance Level | $18.21 | $10.90 |
| Average True Range (ATR) | 0.84 | 0.40 |
| MACD | 0.10 | 0.10 |
| Stochastic Oscillator | 39.97 | 96.87 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World. The company operates in three segments: Powered Vehicles Group, Aftermarket Applications Group, and Specialty Sports Group, of which it derives maximum revenue from Specialty Sports Group segment.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.